Semaglutide vs Tirzepatide Cost (2026): Which Is Cheaper?

At retail list price without insurance, both Wegovy (brand-name semaglutide) and Zepbound (brand-name tirzepatide) are expensive. Wegovy's list price runs approximately $1,300–$1,650 per month depending on dose. Zepbound launched at a similar price point, with monthly costs typically ranging from $1,050–$1,430 per month depending on the dose and whether you're using the vial or autoinjector form.

Eli Lilly's savings program for Zepbound can reduce cost for commercially insured patients, sometimes to around $550/month or less for those who qualify. Novo Nordisk offers a similar savings card for Wegovy. However, these programs typically exclude patients without commercial insurance, so uninsured patients face the full list price.

For most people paying out of pocket, brand-name pricing for either medication is prohibitively expensive. This is why compounded alternatives through telehealth providers have become the primary cash-pay path for both medications.

Compounded semaglutide — the active ingredient in Ozempic and Wegovy — is available through numerous telehealth providers at a fraction of the brand-name price. Programs typically range from $150–$350 per month at starter doses (0.25mg–0.5mg), with prices increasing at higher maintenance doses (1mg–2.4mg for Wegovy-equivalent dosing).

The wide range reflects real differences in what's included: some programs bundle clinical consultations, follow-up visits, and shipping into a single monthly fee. Others charge separately for the clinical component or bill quarterly instead of monthly. When comparing prices, it's worth normalizing to a true monthly equivalent that includes everything you'd pay in the first three months.

FDA enforcement actions around compounded GLP-1 medications have affected availability from some providers. As of early 2026, the landscape has shifted, and some providers that previously offered compounded semaglutide have modified or paused their programs. Always confirm current availability directly with any provider before enrolling.

Compounded tirzepatide — the active ingredient in Mounjaro and Zepbound — typically runs slightly higher than compounded semaglutide at equivalent doses, though the gap is narrower than you might expect. Starter programs often begin in the $175–$350 range, with higher doses pushing toward $400–$500 per month from some providers.

The pricing differential between semaglutide and tirzepatide has narrowed over the past year as more providers entered the compounded tirzepatide space and competition increased. Some weeks the cheapest verified semaglutide program is actually more expensive than the cheapest tirzepatide program — price alone shouldn't drive your medication choice without also factoring in clinical appropriateness.

Similar to semaglutide, compounded tirzepatide availability shifted after FDA regulatory actions in 2025. The current provider landscape is more stable, but confirming availability and current pricing before enrolling remains important.

The same medication can cost $200/month from one provider and $380/month from another — and both prices can be legitimate for their program structures. Several factors drive this variation.

First, what's included in the price matters enormously. Programs that bundle an initial clinical consultation, monthly check-ins, and free shipping into a flat monthly rate will appear more expensive than programs that quote only the medication cost and charge separately for everything else. Always read the fine print to understand what's in the base price.

Second, dose structure affects price significantly. Some providers offer a single starter dose at a low entry price but price higher doses proportionally higher. Others charge a flat rate up to a certain dose threshold. The advertised entry price may not reflect what you'd pay at the dose your provider recommends for you.

Third, program duration affects monthly cost. Some providers require a 3-month or 6-month commitment billed upfront, which can lower the effective monthly cost compared to a monthly subscription but requires a larger initial payment.

At the current state of the market, compounded semaglutide programs tend to have a slightly lower floor price than compounded tirzepatide programs — you're more likely to find a verified semaglutide offer under $200/month than a tirzepatide offer at the same price point. But the gap is smaller than it was a year ago, and it's not consistent across all providers or all dose tiers.

The honest answer is: check the current live pricing. The provider that holds the lowest verified semaglutide price this week may not hold it next week, and the gap between the two medications shifts as providers adjust their programs. The deals directory on this site filters by ingredient and sorts by lowest price, so you can see the current state in one view rather than checking each provider individually.

More importantly, your clinician should drive the medication choice based on your health history, goals, and any prior GLP-1 experience — not cost alone. If the right medication for you is tirzepatide but you're on a tight budget, it's worth asking your provider about lowest-dose starter programs or quarterly billing options that can reduce the effective monthly cost.